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Artemisinin is a plant sesquiterpene lactone that has become an important drug for combating malaria,
especially in regions where resistance to other drugs is widespread. While the mechanism of action is debated,
artemisinin has been reported to inhibit the sarcoplasmic endoplasmic reticulum Ca2 ATPase (SERCA) in
the malaria parasite. Artemisinin is also effective against Toxoplasma in vitro and in vivo, although it is less
potent and, hence, is generally not used therapeutically to treat toxoplasmosis. To explore the mechanism of
action, we generated chemically derived mutants of Toxoplasma gondii that were resistant to growth inhibition
by this compound in vitro. Three artemisinin-resistant (ARTr) mutant clones that differed in their sensitivities
in vitro by three- to fivefold compared with that of the wild-type parasites were obtained. ARTr mutants were
cross-resistant to other derivatives of artemisinin, the most potent of which was artemisone. Resistance was not
due to molecular alterations or differences in the expression of SERCA or other putative targets, such as
proteins that code for multidrug resistance or translationally controlled tumor protein. ARTr mutants were
resistant to the induction of protein secretion from micronemes, a calcium-dependent process that is triggered
by artemisinin. ARTr mutants were not cross-resistant to secretion induced by thapsigargin but were more
sensitive and were unable to regulate cytoslic calcium following treatment with this compound. These studies
implicate calcium homeostasis in the mechanism of action of artemisinins against apicomplexan parasites.
Artemisinin is a natural product that is produced by the
sweet wormwood plant (Artemisia annua). Artemisinin and
various related derivatives are potent antimalarial compounds
that are used to treat human malaria, especially in regions
where resistance to other antimalarial drugs is common (14).
Artemisinins contain an essential endoperoxide ring that is
thought to be activated by reduced iron (Fe2) to form reactive
intermediates (14). In malaria parasite-infected red blood
cells, artemisinin may be activated by heme, which is released
from hemoglobin, leading to reactions with secondary targets
in the parasite and the restriction of growth (22, 23). Direct
labeling studies indicated that one potential target of artemis-
inin is the translationally controlled tumor protein (TCTP) (5),
which binds to artemisinin in Plasmodium falciparum-infected
red blood cells. More recent studies suggest an alternative
mechanism of action based on the ability of artemisinin to
inhibit ATPase6, a sarcoplasmic endoplasmic reticulum-like
Ca2 ATPase (SERCA) of P. falciparum (11). Inhibition of P.
falciparum ATPase6 (PfSERCA) could potentially cause
growth inhibition by altering calcium homeostasis. Thus, arte-
misinin may have a mechanism similar to that of thapsigargin,
a structurally related compound that is a well-known inhibitor
of SERCA (37, 38).
Recent concerns about the possible development of drug
resistance have led to the recommended cessation of mono-
therapy with artemisinin in the field (42). Several potential
mechanisms have been proposed to explain the resistance in
the malaria parasite. Laboratory reports have indicated that
increased numbers of copies of multidrug resistance (MDR)
gene 1 (MDR1) are associated with resistance to artemisinin in
Plasmodium yoelli (12) or, alternatively, with the increased
expression of TCTP (41). Stable resistance to artemisinin has
also been developed in the rodent malaria parasite Plasmo-
dium chabaudi; however, it was not associated with mutations
in ATPase6 or other suspected targets, such as MDR1 (1). The
recent report that mutations in ATPase6 (S769N) are associ-
ated with the elevated resistance of P. falciparum parasites to
artemether in French Guyana (16) supports the hypothesis
that artemisinin and related compounds target SERCA. Other
studies reported elevated levels of MDR1 expression in recru-
descent or recurrent P. falciparum malaria in Southeast Asia in
patients receiving combined therapy with artesunate and me-
floquine, although pressure from the latter drug alone may
explain this result (2). Hence, there remains some question
about the molecular target(s) of artemisinin and about the
potential for the development of resistance to this important
antimalarial drug.
Artemisinin is also effective against Toxoplasma gondii, al-
though the 50% effective concentrations (EC50s) are 50-fold
higher than those for malaria parasites (15, 36). This difference
in sensitivity may relate to molecular differences in the tar-
get(s); differences in activation of the drug; or possibly, differ-
ences in efflux mechanisms, such as those for MDR. Toxo-
plasma gondii is also sensitive to other derivatives, such as
artemether, and to several newly synthesized derivatives that
are structurally similar to artemisinin (17). Artemisinin is also
effective against trypanosomes, where it inhibits Ca2 ATPase
activity in parasite membranes (24), and in inhibiting tumor
* Corresponding author. Mailing address: Department of Molecular
Microbiology, Washington University School of Medicine, 660 S. Eu-
clid Ave., St. Louis, MO 63110. Phone: (314) 362-8873. Fax: (314)
286-0060. E-mail: sibley@borcim.wustl.edu.
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cells in vitro, where the mechanism of action involves calcium
and the induction of apoptosis (28).
The availability of excellent experimental tools for T. gondii
has previously been exploited to identify the molecular basis
for the actions of drugs that disrupt nucleotide or protein
metabolism (30). Combined with techniques for forward ge-
netics (18) and reverse genetics (35), this parasite offers an
excellent experimental model with which drug mechanisms and
the basis of resistance can be explored. Stepwise selection with
increasing concentrations of drug has previously been used to
isolate mutants of T. gondii that are resistant to artemisinin (4).
However, such mutants are difficult to analyze at the molecular
level, as they may arise by multiple alterations in different
targets. On the other hand, chemical mutagenesis results in
specific point mutations induced by DNA alkylating agents,
and this approach has previously been used with T. gondii to
map the molecular basis of a variety of specific inhibitors of
nucleic acid metabolism (31, 32, 34). In the study described in
the present report, we isolated chemically induced mutants of
T. gondii that were resistant to artemisinin in order to explore
the molecular mode of action of this class of drugs.
MATERIALS AND METHODS
Parasites and culture. The strains used in this study were T. gondii RH (ATCC
50838); clone 2F (ATCC 50839), which expresses bacterial -galactosidase (9);
and artemisinin-resistant mutant clone A2 (4). They were maintained as
tachyzoites in human foreskin fibroblast (HFF) cells grown in Dulbecco’s mod-
ified Eagle’s medium with 10 mM HEPES, 44 mM sodium bicarbonate, 10%
fetal bovine serum, 2 mM glutamine, and 10 g/ml gentamicin.
Establishment of ARTr mutants. T. gondii clone 2F was used to produce
chemically induced mutants that were resistant to artemisinin by previously
described procedures (33). Intracellular tachyzoites grown in HFF cells were
treated with 100, 200, or 500 g/ml N-nitroso-N-ethyl-urea (ENU; Sigma-Al-
drich, St. Louis, MO) in serum-free medium for 1 h at 37°C. Parasites treated
with each dose of ENU were harvested and inoculated into separate T25 flasks
containing HFF cells and were selected individually with 2.4, 12, or 300 M
artemisinin. Artemisinin-resistant (ARTr) clones were isolated by single-cell
cloning in 96-well plates containing HFF cells.
Parasite growth assay. Parasites were inoculated into quadruplicate wells per
sample in 96-well plates containing monolayers of HFF cells and were treated
with artemisinin (Sigma); dihydroartemisinin (LKT Laboratories, Inc., St. Paul,
MN); artemether (LKT Laboratories, Inc.); artesunate (LKT Laboratories, Inc.);
and 9-epi-10-deoxoartemisinin, 2-deoxyartemisinin, and artemisone (provided by
R. Haynes and S. Krishna) at concentrations ranging from 10 nM to 100 M for
3 days at 37°C. In parallel, mutants were tested for resistance to 5-fluoro-2-
deoxyuridine (FUDR; Sigma), or pyrimethamine (Sigma). Following treatment,
the culture medium was removed and the monolayers were incubated at 50°C for
10 min in 50 l of lysis buffer (100 mM HEPES pH 8.0, 1 mM MgSO4, 1% Triton
X-100, 5 mM dithiothreitol). After lysis, 160 l of assay buffer (100 mM phos-
phate buffer, pH 7.3, 102 mM -mercaptoethanol, 9 mM MgCl2 [final concen-
trations]) was added to each well and the plate was further incubated for 10
min at room temperature. The reaction was initiated by addition of 40 l of
6.25 mM chlorophenol red--D-galactopyranoside (Roche Diagnostics, Indi-
anapolis, IN) to each well, and the absorbance (the optical density at 570 nm)
was measured. Mean values from three independent experiments were used
to estimate the 50% effective concentrations (EC50s) and EC90s by nonlinear
regression analysis with the KaleidaGraph program (Synergy Software, Read-
ing, PA).
MIC2 secretion assay. Microneme (MIC) secretion assays were performed as
described previously (8, 21). Briefly, freshly egressed parasites were suspended in
assay medium (Dulbecco’s modified Eagle’s medium with 44 mM sodium bicar-
bonate, 20 mM HEPES, 2 mM glutamine, 10 g/ml gentamicin, 3% fetal bovine
serum) and were treated with different concentrations of calcium agonists for 5
or 10 min at 18°C. Following the treatments, the parasites were transferred to
37°C for 2 min to allow secretion, chilled on wet ice, and separated into the
supernatant and cell pellet by centrifugation at 400  g. Proteins were resolved
by 15% sodium dodecyl sulfate-polyacrylamide gel electrophoresis, transferred
to nitrocellulose membranes, and Western blotted by using rabbit anti-mi-
croneme protein 2 (anti-MIC2) antibody (1:10,000) or mouse anti--galactosi-
dase monoclonal antibody 40a-1 (1:300) and horseradish peroxidase-conjugated
goat anti-rabbit or anti-mouse immunoglobulin G (1:10,000) (Jackson Immu-
noresearch Laboratories, West Grove, PA). Signals were detected by using Super
Signal West Pico (Pierce, Rockford, IL).
Intracellular calcium monitoring in live parasites. Intracellular calcium was
monitored by using fura-2-AM {1-[6-amino-2-(5-carboxy-2-oxazolyl)-5-benzo-
furanyloxy]-2-(2-amino-5-methylphenoxy)ethane-N,N,N,N-tetraacetic acid–
pentaacetoxymethyl ester} as described previously (26). Freshly harvested
tachyzoites were washed and resuspended in buffer A (116 mM NaCl, 5.4 mM
KCl, 0.8 mM MgSO4, 5.5 mM D-glucose, 50 mM HEPES, pH 7.4) plus 1.5%
(wt/vol) sucrose and 5.2 M fura-2-AM. Parasites were incubated for 30 min at
26°C and then washed twice with buffer A to remove the extracellular dye. The
parasites were resuspended in buffer A (final density, 2  107 cells/ml), and the
fura-2 fluorescence was monitored at room temperature with a Hitachi F-4500
spectrofluorometer (excitation, 340 and 380 nm; emission, 510 nm). The intra-
cellular calcium concentration ([Ca2]i) was calculated by titration with different
concentrations of Ca2-EGTA buffers by using the ratio of the fluorescence
values at 340 and 380 nm after subtraction of the background fluorescence (25).
The concentrations of the ionic species and complexes at equilibrium were
calculated by using an iterative computer program, as described previously (13).
The traces shown are representative of at least three independent experiments
conducted with separate cell preparations.
Sequencing of additional Ca2 ATPases. Previously identified Ca2 ATPases
in the T. gondii genome (29) were amplified by PCR with gene-specific primers
designed to be specific for the draft 3 annotation of the genome (http://ToxoDB
.org). Total mRNA was extracted from the RH strain of T. gondii by using the
Trizol reagent (Invitrogen, Carlsbad, CA), and cDNAs were generated by using
Superscript3 reverse transcriptase (Invitrogen). Full-length cDNAs were se-
quenced by using gene-specific primers to amplify portions of the gene that were
then directly sequenced by using the ABI technology (performed by SeqWright
DNA Technology Services, Houston, TX). Consensus sequences were aligned by
the using CAP3 program (http://bio.ifom-firc.it/ASSEMBLY/assemble.html),
translated into predicted proteins (http://searchlauncher.bcm.tmc.edu/seq-util
/Options/sixframe.html), aligned using the ClustalW program (http://www.ebi.ac
.uk/clustalw/), and submitted to GenBank.
Real-time qPCR. PCR primers were designed by using the Primer3 program
(http://frodo.wi.mit.edu/cgi-bin/primer3/primer3_www.cgi). Real-time quantita-
tive PCR (qPCR) was performed with a SmartCycler instrument (Cepheid,
Sunnyvale, CA) in a reaction volume of 25 l containing SYBR GreenER qPCR
SuperMix universal (Invitrogen), 0.4 M each primer, and cDNA reverse tran-
scribed from 3 g of total RNA. The reaction conditions were 50°C for 2 min and
95°C for 10 min, followed by 40 cycles of 95°C for 15 s and 60°C for 60 s. Data
analysis was conducted with SmartCycler software (Cepheid). Relative gene
expression levels were calculated as the fold change by using the formula 2 
CT, where CT is the threshold cycle number (CT) for actin minus the CT for
the target gene (see Table 3) and CT is the CT for wild-type strain 2F minus
the CT for mutant RNAs (20). The housekeeping gene encoding actin (ACT1)
was used as a reference control.
Nucleotide sequence accession numbers. The complete cDNA sequences for
the following calcium ATPases from the RH strain were submitted to GenBank:
T. gondii SERCA (TgSERCA; draft 3 annotation, 44.m02594; GenBank acces-
sion no. AY727534), the plasma membrane calcium ATPase (PMCA)-type Ca2
ATPase T. gondii plasma membrane calcium ATPase 1 (TgA1;; draft 3 annota-
tion, 583.m00010; GenBank accession no. EF394334), Golgi-endoplasmic retic-
ulum-type Ca2 ATPase (draft 3 annotation, 641.m01482; GenBank accession
no. EF394333), PMR1-like Ca2 ATPase (draft 3 annotation, 65.m01184; GenBank
accession no. EF394332), and the PMCA-type Ca2 ATPase T. gondii plasma
membrane calcium A2 (TgA2; draft 3 annotation, 44.m02812; GenBank accession
no. EF394331).
RESULTS
Establishment of ARTr mutants of T. gondii. To investigate
the mechanism of resistance to artemisinin, we generated re-
sistant clones of T. gondii following chemical mutagenesis.
ARTr mutants were selected with three different doses of ar-
temisinin (i.e., 2.4, 12, and 300 g/ml) following mutagenesis
with three different doses of ENU (i.e., 100, 200, and 500
g/ml). Following repeated screening from different mutagen-




arch 8, 2014 by W







esis trials, three independent mutants were isolated. Compar-
ison of the growth of these mutants by using the -galactosi-
dase growth assay indicated that they exhibited approximately
two- to threefold increases in the EC50s of artemisinin and
approximately fivefold increases in the EC90s of artemisinin
compared with those for the wild-type parasites (Fig. 1; Table
1). The level of resistance exhibited by these mutants was
independent of the dose of artemisinin used for selection,
which ranged from 2 to 	100 times greater than the EC50.
While the level of resistance exhibited by these mutants is
FIG. 1. Isolation of ARTr mutants of T. gondii. The growth of ARTr mutant parasites versus that of the wild-type (WT) parasites in medium
containing the indicated compounds is shown. Parasite clones were inoculated in 96-well plates containing HFF cells, and parasite growth was
monitored by measurement of -galactosidase activity following 72 h of incubation with different concentrations of compounds (see Materials and
Methods). 200-1, mutant KN200-1; 200-6, mutant KN200-6; 500-10, mutant STL500-10A. The ARTr mutants are defined in Table 1.
TABLE 1. Selection of ARTr mutants and inhibition by artemisinin, FUDR, and pyrimethaminea




EC50 (M) EC90 (M) FUDR Pyrimethamine
Wild type (2F) 0 0 0.80 1.24 0.91 0.21
KN200-1 200 12 1.73 6.85 1.13 0.29
KN200-6 200 2.4 1.51 8.55 1.19 0.27
STL500-10A 500 300 1.80 4.77 0.96 0.24
a Estimates were based on the mean of three independent experiments by using quadruplicate wells per sample over a range of concentrations from 10 nM
to 100 M.
b The ENU concentration used for mutagenesis.
c The artemisinin (ART) concentration used for selection.
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modest, it nonetheless allowed the isolation of clones from a
population of wild-type parasites by continued growth in the
presence of drug over multiple rounds of passage. The resis-
tance phenotype (EC50 of artemisinin) was stable when the
parasites were tested in the presence of artemisinin following
repeated passage in the absence of drug and following cryo-
preservation (data not shown).
Comparison of the growth kinetics of the mutants with those
of the wild-type parasites revealed that ARTr mutants of T.
gondii were also cross-resistant to a variety of semisynthetic
artemisinin derivatives (Fig. 1). Strain KN200-1 was weakly
resistant to artemisinin but was slightly more resistant to the
other compounds tested (Fig. 1). Interestingly, two of the mu-
tants (KN200-6 and STL-500-10A) did not show resistance to
dihydroartemisinin or artesunate, which is rapidly converted to
dihydroartemisinin (Fig. 1). Notably, artemisone was 30-fold
more potent against wild-type parasites (EC50, 30 nM) than
artemisinin (EC50, 800 nM) (Fig. 1). None of the mutants was
resistant to deoxoartemisinin (data not shown), although this
compound was also more than 10-fold less potent against wild-
type parasites (EC50, 10 M). Neither the wild type nor the
mutants showed susceptibility to a derivative not containing
an endoperoxide (2-deoxyartemsinin) (Fig. 1F).
The mechanism of resistance in the ARTr mutants of T.
gondii does not appear to be due to MDR, as they were still
sensitive to the unrelated drugs FUDR and pyrimethamine
(Table 1). Moreover, qPCR of several MDR homologues in
the T. gondii genome failed to show upregulation of these
transcripts (Tables 2 and 3). Previous studies have also
suggested that the upregulation of TCTP in P. yoelli may be
responsible for artemisinin resistance (41). As such, we
checked the parasites for the expression of the mRNA for
the TCTP orthologue in T. gondii. qPCR showed no changes
in the level of expression of TCTP in the ARTr mutants of
T. gondii (Tables 2 and 3), suggesting that the protein en-
coded by this gene is not responsible for the resistance
observed here.
ARTr mutants are resistant to calcium-induced secretion
triggered by artemisinin. We have recently shown that arte-
misinin induces calcium-dependent secretion of MIC proteins
from T. gondii, an effect that is shared by the SERCA inhibitor
thapsigargin (29a). MIC2 secretion can easily be detected by
the release of the reporter protein MIC2 into the supernatant
following stimulation with agonists that raise intracellular cal-
cium levels (7, 21). To determine if ARTr mutants of T. gondii
were sensitive to induced secretion, we tested their responses
to several calcium agonists. While ARTr mutants responded
normally to ethanol, a potent agonist of calcium-mediated se-
cretion (7), they did not secrete MIC2 when they were stimu-
lated with up to 100 M artemisinin (Fig. 2A). Because wild-
type T. gondii secreted MIC2 after treatment with 10 M
artemisinin (Fig. 2A), this result indicates that the mutants
were more than 10-fold resistant to artemisinin-induced secre-
tion. It has been suggested that artemisinin may have a mech-
anism of action similar to that of thapsigargin on the basis of a
shared binding site in SERCA (39). Therefore, we tested
whether the ARTr mutants were cross-resistant to thapsigar-
gin-stimulated MIC2 secretion. No differences in the sensitiv-
ities between the parental wild-type clone (clone 2F) and
ARTr mutants were observed (Fig. 2B). Furthermore, we in-
vestigated ARTr mutant clone A2, which was previously estab-
lished by stepwise selection (4). This mutant was also resistant
to the induction of MIC2 secretion by artemisinin but re-
sponded normally to induction by thapsigargin (data not
shown).
ARTr mutants have profound defects in calcium homeosta-
sis. To further explore the physiological basis for the observed
resistance, ARTr clones were compared to the wild-type par-
asites by using fura-2 to monitor [Ca2]i. ART
r mutants




TgACT1 25.m00007 5-TCCCGTCTATCGTCGGAAAG-3 5-CCATTCCGACCATGATACCC-3
TgSERCA 44.m02594 5-TGATGATCACTGGAGACAACAAGT-3 5-GAGAGGACTTCTTTCTTCTCTTCAA-3
TgA1 583.m00010 5-AGTTGCAGGAGAAGAACTTCAAAT-3 5-AACCTACATGTTTGACTTGTGTGAA-3
TgA2 44.m02812 5-GTTTGCTGATTTCTGGAGTTGAAT-3 5-CACTTCTGTCCAGAGTCTTCTTCTT-3
PMR1 65.m01184 5-GAAAAGGAGTTGAGTTGTCTGCAT-3 5-CAGCAAATGTAAAAACTTCTGTGAA-3
Golgi-ERb 641.m01482 5-AGAACAAGCCTCTAGTCCTCACTCT-3 5-GAGACCAATGATTTTCACTTTGAAT-3
MDR1A 55.m00137 5-TGTCTATGCCTGAAAAAGAAAGTCG-3 5-GGAAGAACACAGCTATGAATCGAGA-3
MDR1B 49.m03125 5-TCTTTCTGGAGTTTGATTTTCGTTG-3 5-GAAGGAGAGAAATGAGCTTGTAGCC-3
MDR2 59.m03673 5-TTTATCCTTCTTGGAGTTTCGCCTA-3 5-GACGTCGAGAAGAGAATGAGAAACA-3
TCTP 50.m03408 5-ATTGCTGACAATAGCGAGGAAGAC-3 5-GCTGCATGTAACCTTTGATGTAGGT-3
a http://ToxoDB.org (19).
b ER, endoplasmic reticulum.
TABLE 3. qPCR analysis of Ca2 ATPases, MDRs, and TCTP
NCBI no. ToxoDBidentifiera Gene
Fold difference for cloneb:
KN200-1 KN200-6 STL500-10A
AY727534 44.m02594 SERCA 0.9 
 0.3 1.0 
 0.6 0.7 
 0.4
EF394334 583.m00010 TgA1 1.3 
 0.1 2.7 
 0.8 1.0 
 0.4
EF394331 44.m02812 TgA2 1.0 
 0.6 1.0 
 0.6 0.7 
 0.5
EF394332 65.m01184 PMR1 1.1 
 0.8 1.1 
 0.3 1.7 
 0.5
EF394333 641.m01482 Golgi-ERc 0.9 
 0.6 1.1 
 0.9 0.9 
 0.2
55.m00137 MDR1A 1.2 
 0.3 0.7 
 0.1 0.8 
 0.2
49.m03125 MDR1B 1.2 
 0.1 0.7 
 0.6 0.6 
 0.1
59.m03673 MDR2 0.9 
 0.1 0.6 
 0.1 0.7 
 0.1
50.m03408 TCTP 1.1 
 0.1 0.9 
 0.2 0.9 
 0.2
a http://ToxoDB.org (19).
b Fold differences versus the value for the wild type (strain 2F), which was set
equal to 1.0. Values are the averages 
 standard deviations of two or three
experiments.
c ER, endoplasmic reticulum.
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showed elevated [Ca2]i compared to those in the wild-type
parasites both in the absence and in the presence of extracel-
lular calcium (Table 4). The elevations in [Ca2]i were approx-
imately 2- to 2.5-fold, and while a change of this magnitude is
relatively small, such elevations may perturb normal calcium
signaling. Treatment of the parasites with artemisinin (20 M)
resulted in only a slight increase in [Ca2]i levels in either the
wild type or the ARTr clones (Fig. 3). As reported previously
(26), the treatment of wild-type parasites with thapsigargin (1
M) resulted in a rapid increase in [Ca2]i, and in wild-type
parasites this response partially recovered toward the baseline
over time (Fig. 3). Similar responses were observed in parasites
incubated in the absence (Fig. 3A) and the presence of extra-
cellular calcium (Fig. 3B). Surprisingly, when the ARTr clones
were stimulated with thapsigargin, [Ca2]i increased dramati-
cally and did not recover, as shown for clone STL500-10A (Fig.
3). This effect was more pronounced in the presence of extra-
cellular calcium (Fig. 3B) than in its absence (Fig. 3A). The
remaining ARTr mutants of T. gondii also showed similar un-
regulated increases in [Ca2]i following treatment with thap-
sigargin (data not shown). Collectively, these results indicate
that ARTr clones have elevated resting [Ca2]i and are unable
to regulate intracellular calcium following treatment with thap-
sigargin.
Expression of TgSERCA and other Ca2 ATPases. Previous
studies have emphasized that amino acid differences in the
putative artemisinin-binding pocket can mediate profound dif-
ferences in the sensitivity of PfSERCA to inhibition in a het-
erologous expression system (39). Additionally, field studies
have suggested that changes outside the transmembrane do-
mains of SERCA might be responsible for resistance to arte-
msinins (1). Therefore, we sequenced the entire coding region of
the SERCA gene in each of the three mutants listed in Table 1.
No differences in amino acid sequences were identified, al-
though the mutant STL-500-10A had a single silent mutation
at position 2508 (C was changed to T). We also sequenced the
SERCA gene from the previously characterized ARTr A2 clone
of T. gondii (4) and found no sequence difference (data not
shown). Hence, the differences in artemisinin sensitivity of
these clones are not due to mutations in the SERCA gene that
would alter the protein. The levels of TgSERCA, as assessed
by Western blotting, were also similar between the wild-type
strain (the 2F clone) and the ARTr mutants (Fig. 4), indicating
that resistance is unlikely to be due to differences in levels of
expression.
Apicomplexans contain a number of other P-type Ca2
ATPases (29), suggesting that resistance might arise by alter-
ations in one of these genes. To examine this potential mech-
FIG. 2. Induction of MIC2 secretion by calcium agonists in wild-
type (WT) and ARTr mutant parasites. (A) MIC2 secretion induced by
artemisinin. Wild-type (strain 2F) parasites secreted MIC2 in re-
sponse to artemisinin, while the mutants (KN200-1, KN200-6, and
STL500-10A) were resistant. Parasites were treated with 30 or 100
M artemisinin (ART) or 1% ethanol (EtOH) for 10 min and
incubated at 37°C for 2 min before separation of the supernatant
and the cell pellet. Fractions were analyzed by sodium dodecyl
sulfate-polyacrylamide gel electrophoresis and Western blotting
with anti-MIC2 ( MIC2)-specific or anti--galactosidase (
-Gal)-specific antibodies. (B) ARTr mutants were not cross-resis-
tant to thapsigargin (TG). Parasites were treated with 10 M thap-
sigargin or 1% ethanol for 10 min at 18°C and were transferred to
37°C for 2 min to stimulate secretion. Samples were analyzed as
described for panel A.







Wild type (RH) 99 
 23 175 
 29
KN200-1 150 
 44 370 
 171
KN200-6 228 
 50 533 
 153
STL500-10A 122 
 30 233 
 31
a Values are means 
 standard deviations from three independent experi-
ments.
b 1 mM EGTA.
c 1 mM CaCl2.
FIG. 3. Western blot analysis indicates similar levels of expression
of TgSERCA in wild-type strain 2F and the ARTr mutants. Cell lysates
of the wild type (WT) and the KN200-1 (200-1), KN200-6 (200-6),
STL500-10A (500), and A2 (A2) mutants were analyzed by Western
blotting with anti-TgSERCA ( TgSERCA) or anti-GRA1 ( GRA1)
antibodies.
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anism, we sequenced the full-length cDNAs for four additional
candidate genes from both wild-type clone 2F and the three
ARTr mutants generated here. Included in this set of genes are
the PMCA-type Ca2 ATPases known as TgA1 and a related
gene, TgA2; a second endoplasmic reticulum-type Ca2
ATPase related to PMR1, and a Golgi-type Ca2 ATPase. No
alterations in the coding regions of these genes were found,
although several allelic differences were noted between the
type I alleles sequenced here and the type II genome used for
reference in the T. gondii genome database (19). Additionally,
we analyzed the levels of expression of each of these genes in
the mutants compared to those in wild-type strain 2F by qPCR.
The levels of expression did not vary by more than approxi-
mately twofold, suggesting that resistance was not due to large
changes in the levels of expression of these particular Ca2
ATPases (Tables 2 and 3).
DISCUSSION
The risk for the development of resistance to artemisinins is
serious, given the current widespread insensitivity of the ma-
laria parasite to other antimalarial drugs. Hence, defining the
mechanism of action and the potential for the development of
resistance is a high priority. Laboratory studies can be highly
informative about the potential for drug resistance under con-
trolled conditions. Additionally, chemical mutagenesis pro-
vides a powerful system for defining the molecular targets in T.
gondii, as shown by previous studies with inhibitors of purine
and pyrimidine metabolism (32–34) and compounds that dis-
rupt the cytoskeleton (9, 27). Chemical mutagenesis was used
here to examine resistance to artemisinin, and while the mo-
lecular basis of resistance was not determined precisely, the
mutants revealed several unexpected findings that have impor-
tant implications. ARTr mutants of T. gondii were only rarely
isolated, and those mutants that were obtained showed only
low-level resistance, although these differences were stable and
clearly sufficient to allow selection. This stands in marked con-
trast to other such screens in which mutants with high-level
resistance have been obtained. These features predict that (i)
the primary target is essential, (ii) the binding site of the
compound is not readily amenable to mutation and/or, (iii)
multiple targets may be present. By using a different strategy of
stepwise selection, ARTr mutants were obtained in the rodent
malaria parasite P. chabaudi, and these mutants also showed
low-level resistance (5- to 10-fold). While only low-level resis-
tance to artemisinins has thus far been obtained in laboratory
studies, this may still be clinically relevant, as shown by field
studies of P. falciparum malaria (16).
The search for chemically stable artemisinins with improved
pharmacokinetics and decreased toxicity has led to the devel-
opment of a large number of derivatives, several of which show
increased activities against the malaria parasite (14, 42). The
sensitivity of wild-type T. gondii to these different semisynthetic
derivatives revealed potencies in the following order: arte-
misone 	 artesunate  artemether 	 dihdyroartemisinin 	
artemisinin. Similar to reports for the malaria parasite (40),
artemisone was more than 10-fold more active than artesunate
in inhibiting wild-type T. gondii and almost 30-fold potent than
artemisinin. Previous studies have indicated that artemether
does not provide protection against toxoplasmosis in the rat
model (6). On the basis of the findings of the present study,
greater in vivo efficacy might be expected with artemisone
treatment of toxoplasmosis.
ARTr mutants of T. gondii were highly stable with continued
passage and survived cryopreservation and resuscitation, indi-
cating that they likely have stable genetic changes due to the
mutations induced by ENU treatment. However, sequencing of
the SERCA gene revealed no molecular differences, nor was
there evidence for amplification or overexpression. Moreover,
the resistance phenotype was not due to an MDR-like mech-
anism. Surprisingly, when ARTr cells were treated with thap-
sigargin, they exhibited extreme elevations in [Ca2]i and
failed to recover to resting levels, unlike wild-type parasites.
One potential mechanism that may explain these findings
would be if recovery from treatment with thapsigargin is not
solely due to the action of SERCA but also is due to another
mechanism that is defective in the ARTr mutants. In addition
FIG. 4. Intracellular calcium levels in T. gondii as monitored
with fura-2-AM. Treatment with artemisinin (ART) showed only a
modest elevation of the [Ca2]i in both the wild type (strain RH)
and an ARTr mutant (clone STL-500-10A). However, treatment
with thapsigargin (TG) induced a rise in [Ca2]i in wild-type para-
sites that partially returned to the baseline level. In contrast, treat-
ment of the ARTr mutant STL500-10A with thapsigargin resulted in
a prolonged elevation of [Ca2]i that did not recover. (A) Cells were
incubated in the absence of extracellular calcium (plus 1 mM
EGTA). (B) Cells were incubated in the presence of extracellular
calcium (1 mM). Arrows indicate the addition of artemisinin (20
M) or thapsigargin (1 M).
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to SERCA, there are four other Ca2 ATPases in the T. gondii
genome, including two plasma membrane Ca2 ATPases
(PMCA type), a second endoplasmic reticulum-type Ca2
ATPase, and a Golgi-type Ca2 ATPase (29). However,
changes in these other Ca2 ATPases also do not appear to
explain the findings for the mutants, as they did not show
differences in sequences or expression levels that would be
consistent with a role in resistance. It remains possible that
subtle changes in Ca2 ATPase expression levels may explain
the elevated calcium levels and homeostasis defects in the
mutants.
Alterations in calcium homeostasis may also arise from dis-
ruption of cation transporters other than P-type Ca2
ATPases. One potential candidate is a plant-like Ca2/H
exchanger (T. gondii gene identifier 25.m01788) that is con-
served in apicomplexans (29). Although little is known about
the role of this transporter in parasites, it may be localized to
the acidocalcisome, an intracellular organelle that is important
in calcium homeostasis (10). Additionally, previous studies
have also shown that disruption of a plasma membrane
Na/H exchanger affects calcium homeostasis and alters cal-
cium ionophore-induced egress in T. gondii (3). Alterations of
these or alternative cation transporters may affect resting cal-
cium levels and result in resistance to artemisinin by an indirect
mechanism. Given the diversity of cation transporters in the
genome, a wider range of potential targets needs to be consid-
ered in analyzing artemisinin resistance in apicomplexans, in-
cluding the malaria parasite.
In Plasmodium, the SERCA orthologue PfATPase6 was re-
ported to be a target of the antimalarial drug artemisinin on
the basis of heterologous expression studies with Xenopus (11).
Consistent with this model, field studies have indicated that the
S769N mutation in PfSERCA is associated with increased re-
sistance to artemether (16). Our results with T. gondii are
consistent with artemisinin playing a role in calcium homeosta-
sis, possibly by affecting SERCA. The expanded use of arte-
misinin derivatives for the treatment of malaria makes the
identification of its molecular target(s) and resistance mecha-
nisms of high priority (42). Further studies on calcium ho-
meostasis in parasites will be important both for determining
the mechanism of action and for understanding the potential
mechanisms of resistance to artemisinins.
ACKNOWLEDGMENTS
We are grateful to Sanjeev Krishna and Richard Haynes for helpful
suggestions and the artemisinin derivatives, Tyler Curiel for providing
the A2 mutant, and Julie Nawas and Cuiying Jiang for expert technical
assistance. Preliminary genomic DNA sequence data were provided by
The Institute for Genomic Research, the Wellcome Trust Sanger In-
stitute, Washington University, and the University of Pennsylvania.
This study was supported by NIH grants AI067051 (to L.D.S.)
and AI68467 (to S.N.J.M.) and by the Uehara Memorial Founda-
tion (to K.N.).
REFERENCES
1. Afonso, A., P. Hunt, S. J. Cheesman, A. C. Alves, C. V. Cunha, V. do Rosario,
and P. Cravo. 2006. Malaria parasites can develop stable resistance to arte-
misinin but lack mutations in the candidate genes atp6 (encoding the sarco-
plasmic and endoplasmic reticulum Ca2 ATPase), tctp, mdr1, and cg10.
Antimicrob. Agents Chemother. 50:480–489.
2. Alker, A. P., P. Lim, R. Sem, N. K. Shah, P. Yi, D. M. Bouth, R. Tsuyuoka,
J. D. Maquire, T. Fandeur, F. Ariey, C. Wongsrichanalai, and S. R.
Meshnick. 2007. PFMDR1 and in vivo resistance to arteunate-methfloquine
in falciparum malaria on the Cambodian-Thai border. Am. J. Trop. Med.
Hyg. 76:641–647.
3. Arrizabalaga, G., F. A. Ruiz, S. Morena, and J. C. Boothroyd. 2004. Iono-
phore-resistant mutant of Toxoplasma gondii reveals involvement of a sodium/
hydrogen exchanger in calcium regulation. J. Cell Biol. 165:653–662.
4. Berens, R. L., E. C. Krug, P. B. Nash, and T. J. Curiel. 1998. Selection and
characterization of Toxoplasma gondii mutants resistant to artemisinin J.
Infect. Dis. 177:1128–1131.
5. Bhisutthibhan, J., X. A. Pan, P. A. Hoosler, D. J. Walker, C. A. Yowell,
J. Carlton, J. B. Dame, and S. R. Meschnick. 1998. The Plasmodium falcip-
arum translationally controlled tumor protein homolog and its reaction with
the antimalarial drug artemisinin. J. Biol. Chem. 273:16192–16198.
6. Brun-Pascaud, M., F. Chau, F. Derouin, and P. M. Girard. 1996. Lack of
activity of artemether for prophylaxis and treatment of Toxoplasma gondii
and Pneumocystis carinii infections in rat. Parasite 3:187–189.
7. Carruthers, V. B., S. N. J. Moreno, and L. D. Sibley. 1999. Ethanol and
acetaldehyde elevate intracellular [Ca2] calcium and stimulate microneme
discharge in Toxoplasma gondii. Biochem. J. 342:379–386.
8. Carruthers, V. B., G. D. Sherman, and L. D. Sibley. 2000. The Toxoplasma
adhesive protein MIC2 is proteolytically processed at multiple sites by two
parasite-derived proteases. J. Biol. Chem. 275:14346–14353.
9. Dobrowolski, J. M., and L. D. Sibley. 1996. Toxoplasma invasion of mam-
malian cells is powered by the actin cytoskeleton of the parasite Cell 84:933–
939.
10. Docampo, R., W. Souza, K. Miranda, P. Rohloff, and S. N. Moreno. 2005.
Acidocalcisomes—conserved from bacteria to man. Nat. Rev. Microbiol.
3:251–261.
11. Eckstein-Ludwig, U., R. J. Webb, I. D. A. van Goethem, J. M. East, A. G. Lee,
M. Kimura, P. M. O’Neill, P. G. Bray, S. A. Ward, and S. Krishna. 2003.
Artemisinins target the SERCA of Plasmodium falciparum. Nature 424:957–
961.
12. Ferrer-Rodriguez, I., J. Perez-Rosado, G. W. Gervais, W. Peters, B. L.
Robinson, and A. E. Serrano. 2004. Plasmodium yoelii: identification and
partial characterization of an MDR1 gene in an artemisinin-resistant line J.
Parasitol. 90:152–160.
13. Grynkiewicz, G., M. Poenie, and R. Y. Tsien. 1985. A new generation of Ca2
indicators with greatly improved fluorescence properties. J. Biol. Chem.
260:3440–3450.
14. Haynes, R. K., and S. Krishna. 2004. Artemisinins: activities and actions.
Microb. Infect. 6:1339–1346.
15. Holfels, E., J. McAuley, D. Mack, W. K. Milhous, and R. McLeod. 1994. In
vitro effects of artemisinin ether, cycloguanil hydrochloride (alone and in
combination with sulfadiazine), quinine sulfate, mefloquine, primaquine
phosphate, trifluoperazine hydrochloride, and verapamil on Toxoplasma
gondii. Antimicrob. Agents Chemother. 38:1392–1396.
16. Jambou, R., E. Legrand, M. Niang, N. Khim, P. Lim, B. Volney, M. T. Ekala,
C. Bouchier, P. Esterre, T. Fandeur, and O. Mercereau-Puijalon. 2005.
Resistance of Plasmodium falciparum field isolates to in vitro artemether and
point mutations of the SERCA-type Pf-ATPase6. Lancet 366:1960–1963.
17. Jones-Brando, L., J. D’Angelo, G. H. Posner, and R. H. Yolken. 2006. In vitro
inhibition of Toxoplasma gondii by four new derivatives of artemisinin. An-
timicrob. Agents Chemother. 50:4206–4208.
18. Khan, A., S. Taylor, C. Su, A. J. Mackey, J. Boyle, R. H. Cole, D. Glover, K.
Tang, I. Paulsen, M. Berriman, J. C. Boothroyd, E. R. Pfefferkorn, J. P.
Dubey, D. S. Roos, J. W. Ajioka, J. C. Wootton, and L. D. Sibley. 2005.
Composite genome map and recombination parameters derived from three
archetypal lineages of Toxoplasma gondii. Nucleic Acids Res. 33:2980–2992.
19. Kissinger, J. C., B. Gajria, L. Li, I. T. Paulsen, and D. S. Roos. 2003.
ToxoDB: accessing the Toxoplasma gondii genome. Nucleic Acids Res. 31:
234–236.
20. Livak, K. J., and T. D. Schmittgen. 2001. Analysis of relative gene expression
data using real-time quantitative PCR and the 2(-delta-delta C(T)) method.
Methods 25:402–408.
21. Lovett, J. L., N. Marchesini, S. N. Moreno, and L. D. Sibley. 2002. Toxo-
plasma gondii microneme secretion involves intracellular Ca2 release from
IP3/ryanodine sensitive stores. J. Biol. Chem. 277:25870–25876.
22. Meschnick, S. R., A. Thomas, A. Ranz, C. M. Xu, and H. Z. Pan. 1991.
Artemisinin (qinghaosu): the role of intracellular hemin in its mechanism of
antimalarial action. Mol. Biochem. Parasitol. 49:181–189.
23. Meshnick, S. R. 1998. Artemisinin antimalarials: mechanisms of action and
resistance. Med. Trop. (Mars) 58(3 Suppl.):13–17.
24. Mishina, Y. V., S. Krishna, R. K. Haynes, and J. C. Meade. 2007. Artemis-
inins inhibit Trypanosoma cruzi and Trypanosoma rhodesiense in vitro growth.
Antimicrob. Agents Chemother. 51:1852–1854.
25. Moreno, S. N., A. E. Vercesi, O. P. Pignataro, and R. Docampo. 1992.
Calcium homeostasis in Trypanosoma cruzi amastigotes: presence of inositol
phosphates and lack of an inositol 1,4,5-trisphosphate-sensitive calcium pool.
Mol. Biochem. Parasitol. 52:251–261.
26. Moreno, S. N. J., and L. Zhong. 1996. Acidocalcisomes in Toxoplasma gondii
tachyzoites. Biochem. J. 313:655–659.
27. Morrissette, N. S., A. Mitra, D. Sept, and L. D. Sibley. 2004. Dinitroanalines
bind alpha-tubulin to disrupt microtubules. Mol. Biol. Cell 15:1960–1968.




arch 8, 2014 by W







28. Mu, D., W. Chen, B. Yu, C. Zhang, Y. W. Zhang, and H. Qi. 2007. Calcium
and survivin are involved in the induction of apoptosis by dihydroartemisin
in human lung cancer SPC-A-1 cells. Methods Fund. Exp. Clin. Pharmacol.
29:33–38.
29. Nagamune, K., and L. D. Sibley. 2006. Comparative genomic and phyloge-
netic analyses of calcium ATPases and calcium-regulated proteins in the
Apicomplexa. Mol. Biol. Evol. 23:1613–1627.
29a.Nagamune, K., W. L. Beatty, and L. D. Sibley. 31 August 2007. Artemisinin
induces calcium-dependent protein secretion in the protozoan parasite Tox-
oplasma gondii. Eukaryot. Cell doi:10.1128/EC.00262-07.
30. Pfefferkorn, E. R. 1990. Cell biology of Toxoplasma gondii, p. 26–50. In D. J.
Wyler (ed.), Modern parasite biology. W. H. Freeman, New York, NY.
31. Pfefferkorn, E. R., and S. E. Borotz. 1994. Toxoplasma gondii: characteriza-
tion of a mutant resistant to 6-thioxanthine. Exp. Parasitol. 79:374–382.
32. Pfefferkorn, E. R., and L. C. Pfefferkorn. 1976. Arabinosyl nucleosides inhibit
Toxoplasma gondii and allow the selection of resistant mutants. J. Parasitol.
62:993–999.
33. Pfefferkorn, E. R., and L. C. Pfefferkorn. 1979. Quantitative studies of the
mutagenesis of Toxoplasma gondii. J. Parasitol. 65:363–370.
34. Pfefferkorn, E. R., and L. C. Pfefferkorn. 1977. Toxoplasma gondii: charac-
terization of a mutant resistant to 5-fluorodeoxyuridine. Exp. Parasitol. 42:
44–55.
35. Roos, D. S., R. G. K. Donald, N. S. Morrissette, and A. L. Moulton. 1994.
Molecular tools for genetic dissection of the protozoan parasite Toxoplasma
gondii. Methods Cell Biol. 45:28–61.
36. Sarciron, M. E., C. Saccharin, A. F. Petavy, and F. Peyron. 2000. Effects of
artesunate, dihydroartemisinin, and an artesunate-dihydroartemisinin com-
bination against Toxoplasma gondii. Am. J. Trop. Med. Hyg. 62:73–76.
37. Thastrup, O., P. J. Cullen, B. K. Drobak, M. R. Hanley, and A. P. Dawson.
1990. Thapsigargin, a tumor promotor, discharges intracellular Ca2 stores
by specific inhibition of the endoplasmic reticulum Ca2-ATPase. Proc. Natl.
Acad. Sci. USA 87:2466–2470.
38. Thastrup, O., A. P. Dawson, O. Scharff, B. Foder, P. J. Cullen, B. K. Drobak,
P. J. Bjerrum, S. B. Christensen, and M. R. Hanley. 1989. Thapsigargin, a
novel molecular probe for studying calcium release and storage. Agents
Actions 27:17–23.
39. Uhlemann, A. C., A. Cameron, U. Eckstein-Ludwig, J. Fischbarg, P. Iserovich,
F. A. Zuniga, M. East, A. Lee, L. Brady, R. K. Haynes, and S. Krishna. 2005.
A single amino acid residue can determine the sensitivity of SERCAs to
artemisinins. Nat. Struct. Mol. Biol. 12:628–629.
40. Vivas, L., L. Rattray, L. B. Stewart, B. L. Robinson, B. Fugmann, R. K.
Haynes, W. Peters, and S. L. Croft. 2007. Antimalarial efficacy and drug
interactions of the novel semi-synthetic endoperoxide artemisone in vitro and
in vivo. J. Antimicrob. Chemother. 59:658–665.
41. Walker, D. J., J. L. Pitsch, M. M. Peng, B. L. Robinson, W. Peters, J.
Bhisutthibhan, and S. R. Meshnick. 2000. Mechanism of artemisinin resis-
tance in the rodent malaria pathogen Plasmodium yoelii. Antimicrob. Agents
Chemother. 44:344–347.
42. Woodrow, C. J., and S. Krishna. 2006. Antimalarial drugs: recent advances
in molecular determinants of resistance and their clinical significance. Cell.
Mol. Life Sci. 63:1586–1596.




arch 8, 2014 by W
ashington University in St. Louis
http://aac.asm
.org/
D
ow
nloaded from
 
